Previous 10 | Next 10 |
2024-03-21 17:47:38 ET Summary GlycomiMetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies. AML is a disease with a poor prognosis, especially for elderly patients, and the...
GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on Wednesday, March 27, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be ...
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 44 th Annual Health Care Conference in Boston, MA on Monday, March 4, 2024 at 12:50 p.m. ET. A live webcast of the panel presentation will...
2024-01-30 13:04:10 ET Summary GlycoMimetics is developing molecules that target specific carbohydrate groups in the treatment of cancer. The company's most advanced project, Uproleselan, has recently shown promising results in a phase 1b/2 study for patients with secondary AML. ...
2024-01-04 16:19:31 ET Gainers: Molecular Partners ( MOLN ) +14% . Sutro Biopharma ( STRO ) +9% . Ribbon Communications ( RBBN ) +7% . Resources Connection ( RGP ) +7% . Pyxis Oncology ( PYXS ) +6% . Losers: 89bio ( ETN...
First in human trial evaluating highly potent E-selectin antagonist, GMI-1687, met its primary and secondary endpoints with no dose-limiting toxicities or safety signals Single ascending dose study confirmed that subcutaneous dosing generated linear pharmacokinetics and achieved target plasma...
FOSTER CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced the completion of enrollmen...
GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the 65th American Society of Hematology (ASH) Annual Meeting will feature two presentations on uproleselan...
2023-11-27 18:51:52 ET Summary GlycoMimetics' uproleselan shows promise in AML, but Phase 3 trial changes introduce data interpretation and regulatory complexities. GlycoMimetics faces increased R&D and G&A expenses; financial health is stable short term but precarious lon...
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference in London, UK on Thursday, November 16, 2023 at 1:30 p.m. GMT/8:30 a.m. ET. A live webcast of the fireside chat ...
News, Short Squeeze, Breakout and More Instantly...
Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population Adverse events were consistent with known side effect profiles of chemotherapy used in the study Comprehensive data analysis with medical, statistical, a...
GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial ...